Navigation Links
Anti-Inflammatory Drug Improves Glycemia, Lowers Inflammation in Obese, Young Adults

Salsalate May Help Reduce Risk for Diabetes, Heart Disease

ALEXANDRIA, Va., Jan. 28 /PRNewswire-USNewswire/ -- An anti-inflammatory drug similar to aspirin may provide an inexpensive means of treating and/or reducing the risk for diabetes in obese young adults by reducing glycemia and lowering inflammation, a study being published in the February issue of Diabetes Care finds.

While researchers have long been aware that high doses of aspirin could reduce blood glucose levels, they have neither understood the mechanisms behind this effect nor been willing to tolerate the risk for stomach bleeding associated with this treatment. However, recent breakthroughs in our understanding of why weight gain is unhealthy point an incriminating finger at inflammation, and suggest that anti-inflammatory treatment strategies might have benefits.

Salsalate -- a nonsteroidal, anti-inflammatory medication similar to aspirin that does not cause bleeding -- has been used for decades to reduce the pain of rheumatoid arthritis. This double-masked, placebo-controlled study found that salsalate substantially reduced glycemia as well as inflammation in obese, young adults, thereby likely reducing the risk of developing type 2 diabetes and heart disease.

"People who are overweight or obese are at high risk for developing type 2 diabetes," said lead researcher Dr. Allison B. Goldfine, Assistant Professor at Harvard Medical School and Research Investigator at the Joslin Diabetes Center. "We know they can reduce that risk by losing weight and increasing physical activity. But many people aren't good at maintaining those types of lifestyle changes over the long-term. Those people can be helped through pharmaceutical interventions. Our study was the first to look at the metabolic changes that occur when you give salsalate to obese people who have not yet developed diabetes. And we're really encouraged by what we found."

Specifically, the study found that people who took 4 grams per day of salsalate reduced fasting glucose levels by 13 percent and C-reactive protein concentrations (a marker of inflammation) by 34 percent. Previous studies have implicated inflammation in the development of type 2 diabetes and heart disease.

The encouraging results from this small population study have prompted the National Institutes of Health to fund a larger, follow-up study that will look at safety and efficacy of targeting inflammation using salsalate in the treatment of type 2 diabetes. The study is currently ongoing at multiple sites across the country.

To reach Dr. Allison B. Goldfine, phone: 617-732-2643 or email:

For more information about the study, please visit

Diabetes Care, published by the American Diabetes Association, is the leading peer-reviewed journal of clinical research into the nation's fifth leading cause of death by disease. Diabetes also is a leading cause of heart disease and stroke, as well as the leading cause of adult blindness, kidney failure, and non-traumatic amputations. For more information about diabetes, visit the American Diabetes Association Web site or call 1-800-DIABETES (1-800-342-2383).

SOURCE American Diabetes Association
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
2. Exercise and yoga improves quality of life in women with early-stage breast cancer
3. Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals
4. Weight-based dosing of ribavirin improves outcomes for patients with hepatitis C
5. Kerry Extends, Improves Small Business Innovation Program
6. Thalidomide Improves Outcomes for Older Myeloma Patients
7. Grape Consumption Improves Antioxidant Capacity in Humans
8. JCSM: CPAP therapy improves symptoms of depression in OSA patients
9. Early intervention dramatically improves outcomes for new dialysis patients
10. New technique improves purity of medicines
11. Novel medication improves ovarian cancer treatment
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from reveals that behind the tendency to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
Breaking Medicine Technology: